Obesity and gastrointestinal hormones-dual effect of angiotensin II receptor blockade and a partial agonist of PPAR-γ

Current Vascular Pharmacology

Volumn 9, Issue 2, 2011, Pages 162-166

  Nakagami, Hironori ^a   Morishita, Ryuichi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Fatty liver; Gut hormones; PPAR ; Telmisartan

Indexed keywords

ADIPOCYTOKINE; AMYLIN; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ANGIOTENSINOGEN; APOLIPOPROTEIN E; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GASTROINTESTINAL HORMONE; GHRELIN; GLIMEPIRIDE; GLUCAGON LIKE PEPTIDE 1; LOSARTAN; NITROPRUSSIDE SODIUM; OXYNTOMODULIN; PANCREAS POLYPEPTIDE; PEPTIDE YY; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; TELMISARTAN; TRIACYLGLYCEROL;

ADIPOSE TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BLOOD PRESSURE REGULATION; CARBOHYDRATE METABOLISM; CARDIOVASCULAR DISEASE; COLON; CORONARY ARTERY ATHEROSCLEROSIS; DRUG EFFECT; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; ENERGY EXPENDITURE; GENE EXPRESSION; HUMAN; HYPERLIPOPROTEINEMIA TYPE 3; HYPERTENSION; ILEUM; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID METABOLISM; LIPID STORAGE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DYSFUNCTION; LIVER FIBROSIS; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PANCREAS; PROMOTER REGION; PROTEIN PROCESSING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; STOMACH; TISSUE GROWTH; TRIACYLGLYCEROL BLOOD LEVEL; UPREGULATION; WEIGHT GAIN;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANIMALS; CARDIOVASCULAR DISEASES; ENDOTHELIUM, VASCULAR; FATTY LIVER; GASTROINTESTINAL HORMONES; HEPATOCYTE GROWTH FACTOR; HUMANS; LIPID METABOLISM; OBESITY; PPAR GAMMA;

EID: 79951715042     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016111794519291     Document Type: Article

References (55)

1. Tatemoto K, Mutt V. Isolation of two novel candidate hormones using a chemical method for finding naturally occurring polypeptides. Nature 1980; 285: 417-8.
2. Mentlein R, Dahms P, Grandt D, Kruger R. Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV. Regul Pept 1993; 49: 133-44.
3. Adrian TE, Ferri GL, Bacarese-Hamilton AJ, Fuessl HS, Polak JM, Bloom SR. Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology 1985; 89: 1070-7.
4. Batterham RL, Cowley MA, Small CJ, et al. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 2002; 418: 650-4.
5. Challis BG, Pinnock SB, Coll AP, Carter RN, Dickson SL, O'Rahilly S. Acute effects of PYY3-36 on food intake and hypothalamic neuropeptide expression in the mouse. Biochem Biophys Res Commun 2003; 311: 915-9.
6. Sloth B, Davidsen L, Holst JJ, Flint A, Astrup A. Effect of subcutaneous injections of PYY1-36 and PYY3-36 on appetite, ad libitum energy intake, and plasma free fatty acid concentration in obese males. Am J Physiol Endocrinol Metab 2007; 293: E604-9.
7. Guo Y, Ma L, Enriori PJ, et al. Physiological evidence for the involvement of peptide YY in the regulation of energy homeostasis in humans. Obesity (Silver Spring) 2006; 14: 1562-70.
8. Doucet E, Laviolette M, Imbeault P, Strychar I, Rabasa-Lhoret R, Prud'homme D. Total peptide YY is a correlate of postprandial energy expenditure but not of appetite or energy intake in healthy women. Metabolism 2008; 57: 1458-64.
9. Scott V, Kimura N, Stark JA, Luckman SM. Intravenous peptide YY3-36 and Y2 receptor antagonism in the rat: effects on feeding behaviour. J Neuroendocrinol 2005; 17: 452-7.
10. Ekblad E, Sundler F. Distribution of pancreatic polypeptide and peptide YY. Peptides 2002; 23: 251-61.
11. Track NS, McLeod RS, Mee AV. Human pancreatic polypeptide: studies of fasting and postprandial plasma concentrations. Can J Physiol Pharmacol 1980; 58: 1484-9.
12. Asakawa A, Inui A, Yuzuriha H, et al. Characterization of the effects of pancreatic polypeptide in the regulation of energy balance. Gastroenterology 2003; 124: 1325-36.
13. Liu YL, Semjonous NM, Murphy KG, Ghatei MA, Bloom SR. The effects of pancreatic polypeptide on locomotor activity and food intake in mice. Int J Obes (Lond) 2008; 32: 1712-5.
14. Bataille D, Tatemoto K, Gespach C, Jornvall H, Rosselin G, Mutt V. Isolation of glucagon-37 (bioactive enteroglucagon/oxyntomodulin) from porcine jejuno-ileum. Characterization of the peptide. FEBS Lett 1982; 146: 79-86.
15. Ghatei MA, Uttenthal LO, Bryant MG, Christofides ND, Moody AJ, Bloom SR. Molecular forms of glucagon-like immunoreactivity in porcine intestine and pancreas. Endocrinology 1983; 112: 917-23.
16. Dakin CL, Gunn I, Small CJ, et al. Oxyntomodulin inhibits food intake in the rat. Endocrinology 2001; 142: 4244-50.
17. Parkinson JR, Chaudhri OB, Kuo YT, et al. Differential patterns of neuronal activation in the brainstem and hypothalamus following peripheral injection of GLP-1, oxyntomodulin and lithium chloride in mice detected by manganese-enhanced magnetic resonance imaging (MEMRI). Neuroimage 2009; 44: 1022-31.
18. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999; 402: 656-60.
19. Kojima M, Kangawa K. Ghrelin: structure and function. Physiol Rev 2005; 85: 495-522.
20. Tschop M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. Nature 2000; 407: 908-13.
21. Wren AM, Small CJ, Ward HL, et al. The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion. Endocrinology 2000; 141: 4325-8.
22. Wren AM, Seal LJ, Cohen MA, et al. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 2001; 86: 5992.
23. Chen HY, Trumbauer ME, Chen AS, et al. Orexigenic action of peripheral ghrelin is mediated by neuropeptide Y and agouti-related protein. Endocrinology 2004; 145: 2607-12.
24. Cummings DE. Ghrelin and the short- and long-term regulation of appetite and body weight. Physiol Behav 2006; 89: 71-84.
25. Rahmouni K, Mark AL, Haynes WG, Sigmund CD. Adipose depot- specific modulation of angiotensinogen gene expression in diet-induced obesity. Am J Physiol Endocrinol Metab 2004; 286: E891-5.
26. Giacchetti G, Faloia E, Mariniello B, et al. Overexpression of the renin-angiotensin system in human visceral adipose tissue in normal and overweight subjects. Am J Hypertens 2002; 15: 381-8.
27. Zorad S, Fickova M, Zelezna B, Macho L, Kral JG. The role of angiotensin II and its receptors in regulation of adipose tissue metabolism and cellularity. Gen Physiol Biophys 1995; 14: 383-91.
28. Janke J, Engeli S, Gorzelniak K, Luft FC, Sharma AM. Mature adipocytes inhibit in vitro differentiation of human preadipocytes via angiotensin type 1 receptors. Diabetes 2002; 51: 1699-707.
29. Sharma AM, Janke J, Gorzelniak K, Engeli S, Luft FC. Angiotensin blockade prevents type 2 diabetes by formation of fat cells. Hypertension 2002; 40: 609-11.
30. Kouyama R, Suganami T, Nishida J, et al. Attenuation of dietinduced weight gain and adiposity through increased energy expenditure in mice lacking angiotensin II type 1a receptor. Endocrinology 2005; 146: 3481-9.
31. de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 2000; 52: 415-72.
32. Benson SC, Pershadsingh HA, Ho CI, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004; 43: 993-1002.
33. Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 2004; 109: 2054-7.
34. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 1995; 270: 12953-6.
35. Rosen ED, Spiegelman BM. PPARgamma: a nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem 2001; 276: 37731-4.
36. Picard F, Auwerx J. PPAR(gamma) and glucose homeostasis. Ann Rev Nutr 2002; 22: 167-97.
37. Nissen SE, Nicholls SJ, Wolski K, et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 2008; 299: 1561-73.
38. Schupp M, Clemenz M, Gineste R, et al. Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity. Diabetes 2005; 54: 3442-52.
39. Uruno A, Sugawara A, Kanatsuka H, et al. Hepatocyte growth factor stimulates nitric oxide production through endothelial nitric oxide synthase activation by the phosphoinositide 3-kinase/Akt pathway and possibly by mitogen-activated protein kinase kinase in vascular endothelial cells. Hypertens Res 2004; 27: 887-95.
40. Makondo K, Kimura K, Kitamura N, et al. Hepatocyte growth factor activates endothelial nitric oxide synthase by Ca(2+)- and phosphoinositide 3-kinase/Akt-dependent phosphorylation in aortic endothelial cells. Biochem J 2003; 374: 63-9.
41. Hayashi K, Nakamura S, Morishita R, et al. In vivo transfer of human hepatocyte growth factor gene accelerates reendothelialization and inhibits neointimal formation after balloon injury in rat model. Gene Ther 2000; 7: 1664-71.
42. Nakagami H, Morishita R, Yamamoto K, et al. Hepatocyte growth factor prevents endothelial cell death through inhibition of bax translocation from cytosol to mitochondrial membrane. Diabetes 2002; 51: 2604-11.
43. Taniyama Y, Morishita R, Aoki M, et al. Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat and rabbit hindlimb ischemia models: preclinical study for treatment of peripheral arterial disease. Gene Ther 2001; 8: 181-9.
44. Nakamura S, Morishita R, Moriguchi A, et al. Hepatocyte growth factor as a potential index of complication in diabetes mellitus. J Hypertens 1998; 16: 2019-26.
45. Morishita R, Nakamura S, Nakamura Y, et al. Potential role of an endothelium-specific growth factor, hepatocyte growth factor, on endothelial damage in diabetes. Diabetes 1997; 46: 138-42.
46. Hayashi S, Morishita R, Nakamura S, et al. Potential role of hepatocyte growth factor, a novel angiogenic growth factor, in peripheral arterial disease: downregulation of HGF in response to hypoxia in vascular cells. Circulation 1999; 100: II301-8.
47. Taniyama Y, Morishita R, Nakagami H, et al. Potential contribution of a novel antifibrotic factor, hepatocyte growth factor, to prevention of myocardial fibrosis by angiotensin II blockade in cardiomyopathic hamsters. Circulation 2000; 102: 246-52.
48. Nakano N, Moriguchi A, Morishita R, et al. Role of angiotensin II in the regulation of a novel vascular modulator, hepatocyte growth factor (HGF), in experimental hypertensive rats. Hypertension 1997; 30: 1448-54.
49. Nakano N, Morishita R, Moriguchi A, et al. Negative regulation of local hepatocyte growth factor expression by angiotensin II and transforming growth factor-beta in blood vessels: potential role of HGF in cardiovascular disease. Hypertension 1998; 32: 444-51.
50. Li Y, Wen X, Spataro BC, Hu K, Dai C, Liu Y. hepatocyte growth factor is a downstream effector that mediates the antifibrotic action of peroxisome proliferator-activated receptor-gamma agonists. J Am Soc Nephrol 2006; 17: 54-65.
51. Angulo P. Nonalcoholic fatty liver disease. New Engl J Med 2002; 346: 1221-31.
52. Angulo P. Obesity and nonalcoholic fatty liver disease. Nutr Rev 2007; 65: S57-63.
53. Fujita K, Yoneda M, Wada K, et al. Telmisartan, an angiotensin II type 1 receptor blocker, controls progress of nonalcoholic steatohepatitis in rats. Digest Dis Sci 2007; 52: 3455-64.
54. Sugimoto K, Qi NR, Kazdova L, Pravenec M, Ogihara T, Kurtz TW. Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis. Hypertension 2006; 47: 1003-9.
55. Jin H, Yamamoto N, Uchida K, Terai S, Sakaida I. Telmisartan prevents hepatic fibrosis and enzyme-altered lesions in liver cirrhosis rat induced by a choline-deficient L-amino acid-defined diet. Biochem Biophys Res Commun 2007; 364: 801-7.